Targeting HER1/EGFR: a molecular approach to cancer therapy.
about
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cellsInflammation-based factors and prognosis in patients with colorectal cancerAre KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsVersican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapyRegulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinomaNanoparticles for Improving Cancer Diagnosis.Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigationTreatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo.The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output.Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro.Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry.Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.Prognostic and predictive response factors in colorectal cancer patients: between hope and reality.Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis.Treatment options in patients with metastatic gastric cancer: current status and future perspectivesRET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.Cigarette-Smoke-Induced Dysregulation of MicroRNA Expression and Its Role in Lung Carcinogenesis.A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.Role of erlotinib in the management of pancreatic cancer.Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathwaysNuclear EGFR suppresses ribonuclease activity of polynucleotide phosphorylase through DNAPK-mediated phosphorylation at serine 776.Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trialThe epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.Lack of EGF receptor contributes to drug sensitivity of human germline cellsEGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer.A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.Protein-based tumor molecular imaging probes.Update on molecular diagnostic tests in head and neck cancerPsoriasis induced by trastuzumab (herceptin®).Profile of erlotinib and its potential in the treatment of advanced ovarian carcinomaNeuregulin-1: a potential endogenous protector in perinatal brain white matter damagemiR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6Molecular targets of breast cancer: AKTing in concertTreatment of recurrent metastatic head and neck cancer: focus on cetuximab.
P2860
Q24810622-1770D9A8-43AE-40F2-BBA0-F92596AD9D97Q26797425-33AF4BE9-D659-4FF3-8831-36E5119C2B87Q26828992-7C25A28D-7AF1-4557-8B2A-0A677D22460BQ28304646-89A83B38-0358-47B4-8E20-0863337B32C5Q28477876-E4843F0C-746B-4EF7-9541-326450B2D4C4Q28749302-7C97A6DB-200E-4E75-B779-BB69A7910335Q30442412-C9FDE2B1-5359-42A9-97B7-E5C51A210A10Q31138109-990DA8F9-E55A-4D25-A888-890ADBE151C3Q33243912-519DEA2A-92C1-4DF2-B62A-FAB70A363EDDQ33385649-F5EA4236-523D-49A4-9B9B-B5A96EFF94C6Q33865354-95DCEEAA-CF90-403D-96D8-EEEFFC3488A3Q33932080-4EB148EE-3995-461D-9887-2BF802060D89Q34281240-801F27BD-C29C-474A-8FBD-8E0396FED270Q34283058-14777280-C8E3-478B-8992-B507B9A0C468Q34292255-52AE3979-5057-471A-AA6D-1148AE806371Q34452683-B4F03A10-3C78-454E-93A4-3D9B17D3B466Q34467133-62CF1555-C597-47A0-A2EE-AFA1682E9639Q34551144-0315E1D8-36FC-42B9-B2A7-07ADB18CEDFBQ34661367-CF90344E-FE20-4000-8F4D-7E6CD25A66C1Q35124840-7B9B8552-8821-484F-BC0C-A7D3BD50165EQ35608615-E912263D-9D6D-4F57-8925-23F5639C9CF0Q35790221-38C328CB-670B-4AA5-902C-C1A000F614FCQ35885511-296F22E2-C4B3-46D7-9AC4-192EF5DBA184Q35919264-D75472AB-55EE-4F7D-96D7-4E7BA327AAD6Q36160185-E36B0E88-933A-4F91-BE1A-7CB406474710Q36225686-E419EC41-8CAE-4ED7-9866-A5EA20D5A300Q36228534-4507BBD8-1F7E-480A-9CF2-93A7A09247DBQ36488138-72577AB7-6349-4D04-8039-38382AD6B2BEQ36616189-C8B8414F-99A9-4B8A-8EAD-AB68A1FF81BCQ36619212-2459703F-1FED-4B60-969F-AFDC490AD7EDQ36659012-A29CACB3-9C07-4C04-A279-AC5FEFA84632Q36696463-90AF4FF1-7BBE-4F7E-B781-D077EC25E60CQ36742911-0B08F3BC-B5FA-4C44-88A3-F9D881ED3068Q36798480-FCC8AF35-28FF-4528-AAFB-A39FF9220690Q36871941-872496A7-28B6-4777-A334-441A0A6D2F60Q36880902-960AE2DF-8616-4CCD-8832-1BBBEA4FECD3Q36997592-3839D1D0-CF9F-4904-9E1B-DFECD05C8503Q37057240-D3BA3E37-7D38-41B6-9172-5088C745E9D6Q37183674-9390FE1D-2CDC-47C8-929B-7153153DCA6FQ37218978-E4B3A9FD-0DEA-4B6F-9F9C-B14A95B75024
P2860
Targeting HER1/EGFR: a molecular approach to cancer therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Targeting HER1/EGFR: a molecular approach to cancer therapy.
@ast
Targeting HER1/EGFR: a molecular approach to cancer therapy.
@en
type
label
Targeting HER1/EGFR: a molecular approach to cancer therapy.
@ast
Targeting HER1/EGFR: a molecular approach to cancer therapy.
@en
prefLabel
Targeting HER1/EGFR: a molecular approach to cancer therapy.
@ast
Targeting HER1/EGFR: a molecular approach to cancer therapy.
@en
P1433
P1476
Targeting HER1/EGFR: a molecular approach to cancer therapy.
@en
P2093
Carlos Arteaga
P433
P577
2003-06-01T00:00:00Z